Treatment of patients with hepatitis C virus on the waiting list

Liver Transplantation

Volumn 9, Issue 11, 2003, Pages

  Everson, Gregory T ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; PEGINTERFERON ALPHA2A; REBETRON; RIBAVIRIN; VIRUS RNA;

ABDOMINAL WALL HERNIA; ADULT; AGED; ARTICLE; BACTERIAL ARTHRITIS; BLOOD; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG COMBINATION; DRUG FATALITY; DRUG RESPONSE; EMPYEMA; FEMALE; GENETICS; GENOTYPE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL ADMISSION; HUMAN; HYPERBILIRUBINEMIA; HYPOTHYROIDISM; LIVER; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; NEUTROPENIA; PANCREATITIS; PRIORITY JOURNAL; RECURRENT DISEASE; RECURRENT VIRUS INFECTION; THROMBOCYTOPENIA; VIROLOGY;

EID: 0242456070     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2003.50247     Document Type: Article

References (16)

1. Everson GT. Natural history of hepatitis C. In: Koff RS, Wu GY, eds. Chronic Viral Hepatitis: Diagnosis and Management. Totowa: Humana Press; 2001.
2. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-562.
3. Trotter JF, Wachs M, Trouillot T, Steinberg T, Bak T, Everson GT, Kam I. Evaluation of 100 patients for living donor liver transplantation. Liver Transpl 2000;6:290-295.
4. Trotter JF, Wachs M, Everson GT, Kam I. Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Engl J Med 2002;346:1074-1082.
5. Trotter J, Schiano T, Wachs M, Kim-Schluger L, Bak T, Kugelmas M, et al. Living donor liver transplantation in hepatitis C patients: Short-term results compared with cadaveric transplantation. Am J Transpl 2001;1S:316A.
6. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002;8:S14-18.
7. Davis GL, Balart LA., Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, et al. Treatment of chronic hepatitis C, with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-1506.
8. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
9. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-356.
10. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
11. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-1499.
12. Fried MW, Shiffman ML, Reddy RK, Smith C, Marino G, Goncales F, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection. N Engl J Med 2002;347:975-982.
13. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman ML, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001; 358:958-965.
14. Hadziyannis S, Cheinquer H, Morgan T, Diago M, Jenson D, Sette HJ. Peginterferon alfa-2a (40kD) (Pegasys) in combination with ribavirin (RBV): Efficacy and safety results from a phase III, randomized, double-blind, multicenter study examining the effect of duration of treatment and RBV dose (abstract). J Hepatol 2002;36:3.
15. Everson GT. Long-term outcome of patients with chronic hepatitis C and decompensated liver disease treated with the LADR protocol [low-accelerating-dose-regimen]. Hepatology 2002;36: 297A.
16. Crippin, JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002;8:350-355.